期刊文献+

霍乱病毒B亚单位作为基因佐剂对单纯疱疹病毒2型DNA疫苗免疫效果的影响

Influence of cholera toxin B subunit as a genetic adjuvant on immune effect of herpes simplex virus type 2 DNA vaccine
原文传递
导出
摘要 目的研究霍乱病毒B亚单位(cholera toxin subunit B,CTB)作为基因佐剂对单纯疱疹病毒2型(herpes simplex virus type 2,HSV-2)DNA疫苗pg D免疫效果的影响。方法将CTB片段克隆至真核表达质粒pc DNA3Kan(p Kan)中,构建基因佐剂pc DNA3Kan-CTB(p CTB)。将BALB/c小鼠随机分为p CTB无疫苗组、pg D/p CTB佐剂组、pg D/p Kan空载体组及PBS对照组,经后腿肌肉多点注射,共免疫3次,每次间隔2周。于末次免疫2周后,经小鼠眼球采血,分离血清,ELISA法检测HSV-2特异性Ig G水平及Ig G1、Ig G2a亚型抗体滴度;制备小鼠脾细胞,MTS法检测小鼠脾脏T细胞增殖能力;将病毒稀释后经腹腔接种小鼠,于免疫2周后,进行HSV-2致死剂量攻毒试验。结果p CTB经双酶切及测序鉴定证明构建正确;pg D/p CTB佐剂组小鼠血清中HSV-2特异性Ig G水平明显高于其他3组(P<0.001),Ig G1和Ig G2a滴度均明显高于pg D/p Kan空载体组(P<0.001),其中Ig G2a增幅更明显,Ig G2a/Ig G1比值与pg D/p Kan空载体组相比,由(1.176±0.11)增加至(1.316±0.07)(P<0.05);pg D/p CTB佐剂组小鼠脾细胞在HSV-2刺激下诱导的特异性T细胞增殖反应明显强于PBS对照组及pg D/p Kan空载体组(P<0.05);攻毒14 d内,pg D/p CTB佐剂组小鼠存活率高达100%。结论 p CTB作为基因佐剂能够显著提高pg D诱导小鼠产生抗原特异性Ig G抗体水平,增强HSV-2特异性T细胞增殖反应,并介导以细胞免疫为主的Th1/Th2混合型免疫反应。 Objective To investigate the influence of cholera toxin B subunit(CTB)as a genetic adjuvant on immune effect of herpes simplex virus type 2(HSV-2)DNA vaccine pg D.Methods CTB gene was cloned into eukaryotic expression vector pc DNA3Kan(p Kan)to construct recombinant plasmid pc DNA3Kan-CTB(p CTB).BALB / c mice were randomly divided into four groups and immunized with p CTB without vaccine,pg D / p CTB,pg D / p Kan PBS as control respectively by intramuscular injection in several sites for 3 times each at an interval of 2 weeks.Serum samples were collected 2 weeks after the last injection and determined for specific Ig G level against HSV-2 as well as Ig G1 and Ig G2 titers by ELISA.Murine splenocytes were prepared and determined for proliferation of T lymphocytes by MTS colorimetric assay.Mice were inoculated i.p.with diluted HSV-2,and challenged with HSV-2 at a lethal dosage 2 weeks later.Results Restriction analysis and sequencing proved that recombinant plasmid p CTB was constructed correctly.The specific Ig G level against HSV-2 in sera of mice in pg D / p CTB group was significantly higher than those in other three groups(P〈.001),while the Ig G1 and Ig G2 a titers were significantly higher than that in pg D / p Kan group(P〈.001),of which Ig G2 a titers increased significantly.Compared with that in pg D / p Kan group,the ratio of Ig G2 a to Ig G1 in pg D /p CTB group increased from(1.176 ± 0.11)to(1.316 ± 0.07)(P〈.05).The proliferation level of HSV-2 specific splenic T lymphocytes in pg D / p CTB group was significantly higher than those in PBS and pg D / p Kan groups(P〈.05).The survival rate of mice in pg D / p CTB group within 14 d after the lethal challenge was 100%.Conclusion As a genetic adjuvant,p CTB increased the specific Ig G antibody level induced by pg D,enhanced the T HSV-2 specific lymphocyte proliferation response,and mediated a mixed Th1 / Th2 with Th1-biased immune response.
出处 《中国生物制品学杂志》 CAS CSCD 2016年第5期458-462,468,共6页 Chinese Journal of Biologicals
基金 浙江省自然科学基金(LY12H19009) 浙江省科技厅计划项目(2011C23002) 浙江省科技厅计划项目(2011F20015)
关键词 霍乱病毒B亚单位 单纯疱疹病毒2型(HSV-2) DNA疫苗 基因佐剂 Cholera toxin B subunit(CTB) Herpes simplex virus type 2(HSV-2) DNA vaccine Genetic adjuvant
  • 相关文献

参考文献21

  • 1CHEN W,PATEL G B,YAN H,et al.Recent advances in the development of novel mucosal adjuvants and antigen delivery systems[J].Hum Vaccin,2010,6(9):pii:11561.
  • 2SUN J B,CZERKINSKY C,HOLMGREN J,et al.Mucosally induced immunological tolerance,regulatory T cells and the adjuvant effect by cholera toxin B subunit[J].Scand J Immunol,2010,71(1):1-11.
  • 3ERIKSSON K,FREDRIKSSON M,NORDSTR M I,et al.Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development[J].Infect Immun,2003,71(4):1740-1747.
  • 4ODUMOSU O,PAYNE K,BAEZ I,et al.Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit[J].Immunobiology,2011,216(4):447-456.
  • 5REBBAPRAGADA A,WACHIHI C,PETTENGELL C,et al.Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract[J].AIDS,2007,21(5):589-598.
  • 6LIU M A.DNA vaccines:an historical perspective and view to the future[J].Immunol Rev,2011,239(1):62-84.
  • 7何方,洪艳,陈勇.一种新型单纯疱疹病毒II型DNA疫苗的构建及其初步研究[J].中国卫生检验杂志,2008,18(6):997-999. 被引量:4
  • 8KARBER G.Determination of LD50[J].Arch Exp Pathol Pharma,1931,162:480.
  • 9AWASTHI S,FRIEDMAN H M.Status of prophylactic and therapeutic genital herpes vaccines[J].Curr Opin Virol,2014,6(1):6-12.
  • 10DUTTON J L,LI B,WOO W P,et al.A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice[J].PLo S One,2013,8(10):e76407.

二级参考文献10

  • 1Kinghorn GR. Epidemiology of genital herpes [ J ]. J lnt Med Res, 1994, 22( Suppl 1 ) : 14A -23A.
  • 2Paz - Bailey G, Ramaswamy M, Hawkes SJ,et al. Herpes simplex virus type 2 : epidemiology and management options in developing countries[J]. Sex Transm Infect, 2007, 83( 1 ) :16 -22.
  • 3Naesens L, De Clercq E. Recent developments in herpesvirus therapy [J]. Herpes, 2001, 8(1) :12 -16.
  • 4Eis - Hubinger AM, Schmidt DS, Schneweis KE. Anti - glycoprotein B monoclonal antibody protects T cell - depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes [ J ]. J Gen Virol, 1993,74 ( Pt 3 ) :379 - 385.
  • 5Milligan GN, Bemstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2 [ J]. J Immunol, 1998, 160(12) :6093 -6100.
  • 6Dudley KL, Bourne N, Milligan GN. Immune protection against HSV - 2 in B - cell - deficient mice [ J ]. Virology, 2000, 270 (2) :454 - 463.
  • 7Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research [ J ]. Clin Microbiol Rev, 2003, 16 ( 1 ) : 96 -113.
  • 8Ramachandran S, Kinchington PR. Potential prophylactic and therapeutic vaccines for HSV infections [ J ]. Curr Pharm Des, 2007, 13 (19) : 1965 - 1973.
  • 9Bourne N, Milligan GN, Schleiss MR, et al. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2[J]. Vaccine, 1996, 14(13) :1230 -1234.
  • 10Kriesel JD, Spruance SL, Daynes RA, et al. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease [J].J Infect Dis, 1996, 173(3):536-541.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部